Advertisement

Drugs

, Volume 58, Issue 1, pp 1–4 | Cite as

Penicillin- and Cephalosporin-Resistant Streptococcus Pneumoniae

Emerging Treatment for an Emerging Problem
  • Keith P. Klugman
  • Charles Feldman
Leading Article

Abstract

The global emergence of pneumococci resistant to antimicrobial therapy has led to dilemmas in the management of pneumococcal infections. The principles of pharmacodynamics predict that penicillin and cephalosporin therapy of pneumonia will be successful against pneumococci with minimum inhibitory concentrations of penicillin up to 4 μg/ml. These predictions are supported by the observations of a number of recent clinical studies. Otitis media therapy is influenced by penicillin-resistance and current recommendations are that amoxicillin is the drug of choice for this infection, given at a double dose of 80 to 90 mg/kg/day. For the therapy of meningitis, cefotaxime or ceftriaxone in maximal doses is recommended and vancomycin may be added if cephalosporin-resistant strains are encountered with reasonable frequency in the population. The new fluoroquinolones with excellent antipneumococcal activity may be considered for use in the setting of pneumonia caused by highly resistant pneumococci and are under evaluation for the management of meningitis.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171–96PubMedGoogle Scholar
  2. 2.
    Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77–83PubMedCrossRefGoogle Scholar
  3. 3.
    Sacho H, Klugman KP, Koornhof KP, et al. Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus [letter]. J Infect 1987; 14: 188–9PubMedCrossRefGoogle Scholar
  4. 4.
    Feldman C, Kallenbach JM, Miller SD, et al. Community-acquired pneumonia due to penicillin-resistant pneumococci. NEngl JMed 1985; 313: 615–7CrossRefGoogle Scholar
  5. 5.
    Pallares R, Gudiol F, Linares J, et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med 1987; 317: 18–22PubMedCrossRefGoogle Scholar
  6. 6.
    Austrian R, Gold J. Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964; 60: 759–76PubMedGoogle Scholar
  7. 7.
    Klugman KP. Management of antibiotic-resistant pneumococcal infections. J Antimicrob Chemother 1994; 34: 191–3PubMedCrossRefGoogle Scholar
  8. 8.
    Feldman C, Klugman K. Antibiotic-resistant pneumococcal pneumonia. S Afr Med J 1996; 86: 28–30PubMedGoogle Scholar
  9. 9.
    Friedland IR, Klugman KP. Failure of chloramphenicol in penicillin-resistant pneumococcal meningitis. Lancet 1992; 339: 405–8PubMedCrossRefGoogle Scholar
  10. 10.
    Bradley JS, Connor JD. Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis J 1991; 10: 871–3PubMedCrossRefGoogle Scholar
  11. 11.
    Friedland IR, McCracken Jr GH. Management of infections by antibiotic-resistant Streptococcus pneumoniae N Engl J Med 1994; 331: 377–82PubMedCrossRefGoogle Scholar
  12. 12.
    Klugman KP, Friedland IR, Bradley JS. Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1988–92PubMedCrossRefGoogle Scholar
  13. 13.
    Friedland IR, Klugman KP. Cerebrospinal fluid bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in children with meningitis treated with high dosage cefotaxime. Antimicrob Agents Chemother; 41: 1888–91Google Scholar
  14. 14.
    Klugman KP, Dagan R, Meropenem Meningitis Study Group. A randomized comparison of meropenem with cefotaxime for the treatment of bacterial meningitis. Antimicrob Agents Chemother 1995; 39: 1140–6PubMedCrossRefGoogle Scholar
  15. 15.
    Friedland IR, Klugman KP. Antibiotic-resistant pneumococcal disease in South African children. Am J Dis Child 1992; 146: 920–3PubMedGoogle Scholar
  16. 16.
    Choi E-H, Lee H-J. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin Infect Dis 1998; 26: 1346–54PubMedCrossRefGoogle Scholar
  17. 17.
    Deeks SL, Palacio R, Ruvinsky R, et al. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. The Streptococcus pneumoniae Working Group. J Pediatr 1999 Feb; 103(2): 409–13CrossRefGoogle Scholar
  18. 18.
    Silverstein M, Chumpa A, Bachur R, et al. Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia [abstract K-90]. Toronto, Canada: ICAAC, 1997; P343Google Scholar
  19. 19.
    Buckingham SC, Brown SP, San Joaquin VH. Break-through bacteremia and meningitis during treatment with cephalospo-rins parenterally for pneumococcal pneumonia. J Pediatr 1998; 132: 174–6PubMedCrossRefGoogle Scholar
  20. 20.
    Pallares T, Linares J, Vadillo M, et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995; 333: 474–80PubMedCrossRefGoogle Scholar
  21. 21.
    Destache CJ, Pakiz CB, McConnell S et al. Effect of penicillin (PCN) susceptibility on hospitalization length and mortality in Streptococcus pneumoniae infections [abstract K-89]. 37th International Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28–Oct 1; Toronto, P343Google Scholar
  22. 22.
    Plouffe JF, Breiman RF, Facklam RR. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA 1996; 275: 194–8PubMedCrossRefGoogle Scholar
  23. 23.
    Mularczyk M, Leophonte P, Rouquet RM, et al. Resistant and susceptible penicillin pneumococcal pneumonia-comparative study [abstract K-88]. 37th International Conference on Antimicrobial Agents and Chemotherapy 1997 Sep 28–Oct 1; Toronto, P343Google Scholar
  24. 24.
    Scaglione F, Raichi M, Fraschini F. Serum protein binding and extravascular diffusion of methoxyimino cephalosporins: time courses of free and total concentrations of cefotaxime and ceftriaxone in serum and pleural exudate. J Antimicrob Chemother 1990; 26(A Suppl.): 1–10PubMedCrossRefGoogle Scholar
  25. 25.
    Craig WA, Andes D. Pharmacokinetic and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255–9PubMedCrossRefGoogle Scholar
  26. 26.
    Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996; 15: 980–5PubMedCrossRefGoogle Scholar
  27. 27.
    Dagan R, Liebovitz E, Greenberg D, et al. Early eradication of pathogens from middle ear fluid during antibiotic treatment of acute otitis media is associated with improved clinical outcome. Pediatr Infect Dis J 1998; 17: 776–82PubMedCrossRefGoogle Scholar
  28. 28.
    Dowell S, Butler J, Giebink S, et al. Acute otitis media: management and surveillance in the era of pneumococcal resistance: a report from the Drug-resistant streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999 Jan; 18: 1–9PubMedGoogle Scholar
  29. 29.
    Kaplan SL, Mason EO. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11: 628–44PubMedGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.MRC/SAIMR/WITS Pneumococcal Diseases Research Unit, Department of Clinical Microbiology and Infectious DiseasesSouth African Institute for Medical Research and the University of the WitwatersrandJohannesburgSouth Africa
  2. 2.Division of Pulmonology, Department of MedicineJohannesburg Hospital and the University of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations